Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Eli Lilly And Co. LLY, a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, ...

Indiana business owners and investors had a solid 2024. Jane King, a NASDAQ Analyst, says 2024 was a banner year for the ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

An 81-year-old pedestrian was transported to the hospital in serious condition after being struck by an auotmobile near the intersection of Rycroft and Ahana streets at 7 p.m. Friday. No further ...